Piracetam
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
Piracetam: From No UK-Licensed Indication to Osteoarthritis (Predicted)
One-Sentence Summary
Piracetam (DrugBank DB09210) currently holds no UK marketing authorisation, and no original indication data is available in this evidence pack. The TxGNN model predicts it may be effective for Osteoarthritis, but this prediction is currently supported by 0 clinical trials and 0 publications — it rests on the knowledge-graph score alone.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not available — no UK marketing authorisation on record |
| Predicted New Indication | Osteoarthritis |
| TxGNN Prediction Score | 98.45% |
| Evidence Level | L5 (model prediction only, no supporting trials or literature) |
| UK Market Status | Not marketed |
| Number of Marketing Authorisations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available for Piracetam in this evidence pack. Without MOA information, and with no UK-licensed indication on record to compare against, it is not possible to construct a pharmacologically grounded rationale for extending Piracetam’s use to osteoarthritis. The osteoarthritis prediction (rank 1, score 98.45%) is derived purely from the TxGNN knowledge-graph model and is not corroborated by any clinical trial or published literature.
It is worth noting that lower-ranked candidates in this evidence pack — rheumatoid arthritis (rank 3) and hepatic porphyria (rank 5) — do have some indirect supporting literature. However, this literature concerns Levetiracetam, a different racetam-class anticonvulsant, not Piracetam itself, and is limited to preclinical/animal studies and case reports. This is class-level indirect evidence at best and should not be interpreted as direct support for Piracetam in any of the predicted indications, including osteoarthritis.
Given the absence of MOA data, the absence of a known original indication, and the complete lack of disease-specific evidence for osteoarthritis, mechanistic plausibility cannot currently be assessed.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
UK Market Information
Piracetam is not currently marketed in the UK and has no marketing authorisations on record in this evidence pack.
Safety Considerations
Please refer to the SmPC and BNF for safety information. Report suspected adverse reactions via the Yellow Card Scheme.
Note: since Piracetam holds no UK marketing authorisation, no UK SmPC currently exists. Key warnings, contraindications and drug–drug interaction data are all recorded as data gaps in this evidence pack, and the missing label/warning data (DG001) is flagged as a Blocking gap that prevents any safety pre-assessment.
Conclusion and Next Steps
Decision: Hold
Rationale: The top-ranked prediction (osteoarthritis) has no supporting clinical trials or literature and relies solely on a TxGNN model score (L5 evidence). Combined with the absence of mechanism of action data, the absence of a UK marketing authorisation, and a Blocking data gap on safety warnings/contraindications, there is currently insufficient basis to advance this candidate beyond an exploratory stage.
To proceed, the following is needed:
- Mechanism of action (MOA) data for Piracetam (DrugBank query, per DG002)
- Regulatory label data — warnings and contraindications, e.g. via TFDA or an equivalent regulator with a marketed product (per DG001, currently Blocking)
- Disease-specific clinical or preclinical evidence directly involving Piracetam (not the Levetiracetam class) for osteoarthritis
- If pursuing the rheumatoid arthritis or hepatic porphyria leads instead, a targeted literature review to determine whether the Levetiracetam-class mechanism (JAK2/STAT3, TLR4/MAPK modulation; renal vs. hepatic clearance profile) genuinely extends to Piracetam
- Confirmation of UK/EU regulatory status and any historical licensing history for Piracetam
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.